Immune Checkpoint Inhibitors Trials in Urothelial Cancer: Recent Updates and Future Outlook - Andrea Apolo

Alicia Morgans interviews Andrea Apolo who details the trial design and current status of the Phase III adjuvant AMBASSADOR trial for patients with high-risk muscle-invasive bladder cancer (MIBC) and the need to develop additional treatment options for patients who are resistant to chemotherapy and develop recurrent disease.  The AMBASSADOR trial aims to answer the question if there is a benefit to receiving pembrolizumab earlier and if that will change overall survival in patients.  Andrea also details other abstracts in bladder cancer that she is involved with at the NIH and presented at the ASCO GU 2019 meeting.

Biographies:

Andrea B. Apolo, MD, Chief of the Bladder section of Genitourinary Malignancies Branch at the National Cancer Institute (NIH) and a NIH Lasker Clinical Research Scholar

Alicia Morgans, MD, MPH, Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe